P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Aug 2025 | Trial primary completion date: Dec 2023 --> Aug 2025
8 months ago
Trial completion date • Trial primary completion date • Oncolytic virus
P1, N=30, Not yet recruiting, City of Hope Medical Center | Trial completion date: Jun 2023 --> Dec 2023 | Initiation date: Dec 2021 --> Apr 2022 | Trial primary completion date: Jun 2023 --> Dec 2023
over 2 years ago
Trial completion date • Trial initiation date • Trial primary completion date • Oncolytic virus
We recently completed a first-in-human trial assessing the safety of a single intracerebral dose of NSC-delivered CRAd-Survivin-pk7 (NSC.CRAd-S-pk7) combined with radiation and chemotherapy in newly diagnosed high-grade glioma patients...Here, we report IND-enabling studies in which an improvement in treatment efficacy is achieved in immunocompetent mice by administering multiple treatment cycles intracerebrally. The results imply that pre-existing immunity does not preclude therapeutic benefits attainable by administering multiple rounds of an oncolytic adenovirus directly into the brain.